

PROTOCOL CHANGES

The following Protocol changes have been approved by the Trial Management Committee and the new version will be sent to sites for submission to their HREC over the coming weeks.

Inclusion Criteria

Version 1.2	Version 1.3
N/A	ERI* \geq 2.0 IU/kg/week/gHb for EPO treated patients and \geq 0.01 μ g/kg/week/g Hb for darbepoetin treated patients.
minimum Hb $<$ 110 g/L for \geq 12 weeks.	minimum \leq 120 g/L (no time specification).
minimum EPO dose \geq 200 IU/kg/week and darbepoetin \geq 1 μ g/kg/week.	Criteria deleted.


Exclusion Criteria

Version 1.2	Version 1.3
Active peptic ulcer disease	History of <i>major</i> gastrointestinal bleeding <u>or</u> <i>any</i> GI bleed in last 12 weeks

*ERI is the erythropoietin resistance index (ERI) which is calculated as the weekly weight-adjusted dose of EPO divided by the haemoglobin level.

The HERO Trial Recruitment Status

March 2010



AUSTRALASIAN
KIDNEY TRIALS

Donna Reidlinger
Project Officer

Phone: 07 3240 5961
Fax: 07 3240 5663

d.reidlinger@uq.edu.au

University of Queensland
School of Medicine

Princess Alexandra Hospital
Ground Level
Building 33
Ipswich Road
Woolloongabba QLD 4102

